ClinicalTrials.gg
CompletedNCT00548860Updated Feb 20, 2018Results posted

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

A Phase 3 interventional study of Ferric Carboxymaltose and Standard Medical Care (SMC) in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,018
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.

Enrollment
3rd of 54
2,018 · median 156
Started
2007
with 2 others
Phase 3
23 of 54
none open now
Registered
7th of 54
by date
Lead sponsor
11 of 54
American Regent, Inc.

Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 3rd largest by enrollment, is one of 3 that started in 2007, is one of 23 in phase 3, and was the 7th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing ferric carboxymaltose in Anemia, or all of them as a file.
02

Study summary

The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.

03

Conditions studied

  • Anemia

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female with iron deficiency anemia
  • Hg \</= 11 g/dL

Exclusion criteria

Exclusion Criteria:

  • Previous participation in a FCM trial
  • Known to FCM
  • History of anemia other that anemia due to heavy uterine bleeding or the post partum state
  • current history of GI bleeding
  • Received IV Iron within the month prior
  • Anticipated need for surgery
  • history
  • or ALT greater than normal
  • Received an drug within 30 days of screening
  • Pregnant or sexually active females who are not willing ot use an effective form of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,018 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose (FCM)

    Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)

    Drug: Ferric Carboxymaltose

  • Active comparator
    Standard Medical Care (SMC)

    Varied as determined by the Investigator

    Drug: Standard Medical Care (SMC)

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.

    Evaluate the safety of the maximum administered dose, 15 mg/kg (up to a maximum 1,000 mg) of FCM compared to SMC. The primary safety endpoint was the incidence of Serious Adverse Events (SAE's).

    Time frame: From Day 0 through 30 days after the last dose of study drug.

07

Results

Posted May 29, 2015

Participant flow

Hospitals and medical clinics

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM)Standard Medical Care (SMC)
Started9961022
Completed860847
Not completed136175

Outcome measures

PrimaryEvaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.

Evaluate the safety of the maximum administered dose, 15 mg/kg (up to a maximum 1,000 mg) of FCM compared to SMC. The primary safety endpoint was the incidence of Serious Adverse Events (SAE's).

Time frame:
From Day 0 through 30 days after the last dose of study drug.
Reported as:
Number · participants
Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.
participantsFerric Carboxymaltose (FCM)Standard Medical Care (SMC)
Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.622

Adverse events

Collected over 1 year and 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)—6/996 (0.6%)9/996 (0.9%)
Standard Medical Care (SMC)—22/1,022 (2.2%)79/1,022 (7.7%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventFerric Carboxymaltose (FCM)Standard Medical Care (SMC)
MenorrhagiaReproductive system and breast disorders0/9966/1022
Uterine hemorrhageReproductive system and breast disorders1/9965/1022
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/9965/1022
Postpartum hemorrhagePregnancy, puerperium and perinatal conditions0/9962/1022
AnemiaBlood and lymphatic system disorders1/9960/1022
CholecystitisHepatobiliary disorders1/9961/1022
Necrotising FasciitisInfections and infestations1/9960/1022
Postoperative abscessInfections and infestations1/9960/1022
LymphadenitisBlood and lymphatic system disorders0/9961/1022
Abdominal adhesionsGastrointestinal disorders0/9961/1022
Most frequent other events
Most frequent other events
EventFerric Carboxymaltose (FCM)Standard Medical Care (SMC)
ConstipationGastrointestinal disorders9/99679/1022

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ferric Carboxymaltose (FCM)Standard Medical Care (SMC)Total
<=18 years252752
Between 18 and 65 years9719951966
>=65 years000
Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM)Standard Medical Care (SMC)Total
Mean31.2 ± 9.3631.4 ± 8.9831.3 ± 9.17
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)Standard Medical Care (SMC)Total
Female99610222018
Male000
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM)Standard Medical Care (SMC)Total
United States99610222018
08

Study locations

1 site
  • Luitpold Pharmaceuticals
    Norristown, Pennsylvania 19403, United States
09

References and documents

Publications

  • Seid MH, Butcher AD, Chatwani A. Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. Anemia. 2017;2017:9642027. doi: 10.1155/2017/9642027. Epub 2017 Apr 13. PubMed 28487769 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Mar 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2007
First posted
Oct 24, 2007
Start
Oct 2007
Primary completionActual
Mar 2009
CompletionActual
Jul 2009
Results first posted
May 29, 2015
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00548860
Responsible party
Sponsor
First posted
Oct 24, 2007
Start date
Oct 2007
Primary completion
Mar 2009
Completion
Jul 2009
Results posted
May 29, 2015
Last update
Feb 20, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion